Description

A 67-year-old man with progressive dysphagia and 15% weight loss was diagnosed with a partly obstructing oesophageal adenocarcinoma arising in an inlet patch. This extended for 7 cm from the postcricoid oesophagus, and was staged as cT3N3M0. Following bougie dilation, a percutaneous endoscopic gastrostomy (PEG) tube was inserted for nutritional support before commencing radiation (50.4 Gy) and chemotherapy (3 cycles of FOLFOX (Folinic acid, 5-Fluorouracil and Oxaliplatin)) for 6 weeks. He had a complete endoscopic and radiological response. Supplemental overnight PEG feeding was continued.

On clinical review 3 months later, a tumour mass, with purulent discharge, was evident beside the PEG tube (figure 1A). This was confirmed as adenocarcinoma. On Positron Emission Tomography-Computed Tomography (PET-CT), 18-fluorodeoxyglucose (FDG) uptake was localised to this site and extended to the stomach (figure 1B). Following discussion at the multidisciplinary team meeting (MDT), he underwent an en bloc resection, including the anterior abdominal and anterior gastric wall around the internal retention bolster. He remains disease-free 5 months later.

• Download figure
• Open in new tab
• Download powerpoint

Figure 1

(A) Metastatic adenocarcinoma at percutaneous endoscopic gastrostomy (PEG) site from a primary oesophageal tumour. (B) Positron Emission Tomography-Computed Tomography (PET-CT), image showing 18-fluorodeoxyglucose (FDG) avid metastasis at the PEG insertion site.

Proximal oesophageal cancers are predominantly squamous cell cancer (SCC), with adenocarcinoma constituting approximately 10% of the cases.1 An inlet patch is an area of heterotopic gastric mucosa found in the proximal oesophagus in up to 10% of the population, and adenocarcinoma can develop from this patch, although rarely.2 3 Adenocarcinoma is not as sensitive to radiation as SCC, but surgery for this case would have required resection of the larynx, pharynx and oesophagus, and in combination with locally advanced disease, these considerations underpinned a management decision to treat with radical chemoradiation.

The likely causation of localised metastatic tumour development in this case was malignant cell capture on the PEG bolster when drawn through the obstructing tumour site, with implantation in the stomach wall, and subsequent external progression. A meta-analysis reports the overall rate of PEG site metastasis from upper aerodigestive tract cancers as approximately 0.5%, with 74 published cases; however, the majority are from head and neck cancer, and all previous reports of gastrostomy site metastasis from oesophageal primary are SCC, with 37% being in association with other metastases.4–6 Stockeld et al reported an interesting case of adenocarcinoma in a gastric conduit in a patient with a prior PEG, possibly also representing implantation at insertion.7

Different methods of PEG placement do not differ significantly in the incidence of development of abdominal wall metastasis.8 A study evaluating malignant cell seeding at PEG site in patients with oropharyngeal and oesophageal cancers showed that cancer cell transfer can be demonstrated on cytology in up to 22.5% of the cases, which at 3–6-month follow-up reduces to 9.4%; however, no patient in this study developed a visible tumour mass.9 The local factors determining successful implantation of tumour cells and progression in this case are unclear.

Notwithstanding, the representation at 3 months was localised clinically and on PET-CT to the PEG site. The primary site was tumour free based on imaging, endoscopy and biopsy. At MDT, all approaches were discussed, including further chemotherapy and radiotherapy, but surgery was selected, to render him disease free, and palliate from the unpleasant symptoms of a necrotic, purulent tumour.